Updates from the Exchange

A new analysis calls for increased U.S. investment in multipurpose prevention technologies (MPTs) including female condoms, vaginal rings...

The UK's lead regulatory agency has authorized self-injection of Pfizer's subcutaneous injectable contraceptive...

WHO has released the much-anticipated fifth edition of its comprehensive Medical Eligibility Criteria for Contraceptive Use

FP2020 has introduced a new online knowledge platform designed to advance global and country-level progress in family planning.

The levonorgestrel-releasing intrauterine system (LNG-IUS) was approved for use by women to prevent pregnancy for up to three years.

As we push for new innovation in contraceptive research and development, we must remember the important past breakthroughs in the field. One

Released by Policy Cures on February 4, 2015, the G-FINDER Reproductive Health 2014 report discusses global investment into research and dev

Preliminary findings from new research published in the journal Obstetrics and Gynecology indicate that the 52-mg levonorgestrel intrauterin

U.S. Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg has announced her plans to step down at the end of March 2015.

Does the use of hormonal contraception significantly increase the risk of HIV acquisition?

More than 120 million women across the European Union will soon be able to access ellaOne® emergency contraception (EC) without a...